David Scott Jones - Jan 22, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jan 22, 2024
Transactions value $
-$435,042
Form type
4
Date filed
1/24/2024, 04:50 PM
Previous filing
Jan 9, 2024
Next filing
Jan 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $291K +28.8K +75.73% $10.13 66.7K Jan 22, 2024 Direct
transaction EYPT Common Stock Options Exercise $62.1K +5.42K +8.12% $11.47 72.1K Jan 22, 2024 Direct
transaction EYPT Common Stock Sale -$120K -5.42K -7.51% $22.24 66.7K Jan 22, 2024 Direct F1
transaction EYPT Common Stock Sale -$652K -28.8K -43.1% $22.69 38K Jan 22, 2024 Direct F2
transaction EYPT Common Stock Options Exercise $5.16K +400 +1.05% $12.90 38.4K Jan 23, 2024 Direct
transaction EYPT Common Stock Options Exercise $1.63K +500 +1.3% $3.26 38.9K Jan 23, 2024 Direct
transaction EYPT Common Stock Sale -$10K -400 -1.03% $25.00 38.5K Jan 23, 2024 Direct
transaction EYPT Common Stock Sale -$12.5K -500 -1.3% $25.00 38K Jan 23, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5.42K -54.16% $0.00 4.58K Jan 22, 2024 Common Stock 5.42K $11.47 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -28.8K -47.92% $0.00 31.3K Jan 22, 2024 Common Stock 28.8K $10.13 Direct F4
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -400 -1.62% $0.00 24.2K Jan 23, 2024 Common Stock 400 $12.90 Direct F5
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -500 -0.55% $0.00 91.2K Jan 23, 2024 Common Stock 500 $3.26 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
F4 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
F5 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
F6 The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.